Is MAGE-1 expression in metastatic malignant melanomas really helpful?

American Journal of Surgical Pathology

Volumn 28, Issue 7, 2004, Pages 883-888

  Gajjar, Nupoor A ^a   Cochran, Alistair J ^a   Binder, Scott W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunotherapy; MAGE 1; Melanoma; Tyrosinase

Indexed keywords

BIOCHEMICAL MARKER; MELANOMA ANTIGEN 1; MONOPHENOL MONOOXYGENASE; PROTEIN S 100;

ADULT; AGED; ARTICLE; CANCER CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PROTEIN EXPRESSION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN METASTASIS; TARGET CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOANTIGENS; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 3042836990     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200407000-00006     Document Type: Article

References (25)

1. Bodey B, Siegel SE, Kaiser HE. MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. In Vivo. 2002;16:583-588.
2. Cebon J, MacGregor D, Scott A, et al. Immunotherapy of melanoma: targeting defined antigens. Australas J Dermatol. 1997;38(suppl 1):66-72.
3. Cheville JC, Roche PC. MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors. Mod Pathol. 1999;12:974-978.
4. Cochran AJ, Bhuta S, Paul E, et al. The shifting patterns of metastatic melanoma. Clin Lab Med. 2000;20:759-783, vii.
5. Corrias MV, Scaruffi P, Occhino M, et al. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer. 1996;69:403-407.
6. Coulie PG. Cancer immunotherapy with MAGE antigens. Suppl Tumori. 2002;1(suppl):63-65.
7. De Plaen E, Naerhuyzen B, De Smet C, et al. Alternative promoters of gene MAGE4a. Genomics. 1997;40:305-313.
8. Fetsch PA, Steinberg SM, Riker AI, et al. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look. Cancer. 2001;93:409-414.
9. Gillespie AM, Coleman RE. The potential of melanoma antigen expression in cancer therapy. Cancer Treat Rev. 1999;25:219-227.
10. Gudat F, Zuber M, Durmuller U, et al. The tumour-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch. 1996;429:77-81.
11. Hoon DS, Yuzuki D, Hayashida M, et al. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol. 1995;154:730-737.
12. Juretic A, Spagnoli GC, Schultz-Thater E, et al. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol. 2003;4:104-109.
13. Kim YM, Lee YH, Shin SH, et al. Expression of MAGE-1, -2, and -3 genes in gastric carcinomas and cancer cell lines derived from Korean patients. J Korean Med Sci. 2001;16:62-68.
14. Kuwahara A, Katano M, Nakamura M, et al. Expression of melanoma antigen-encoding gene-1 predicts lymph node involvement in early gastric carcinomas. Dig Dis Sci. 2001;46:262-267.
15. Park JH, Lee SW. Hypertonicity induction of melanoma antigen, a tumor-associated antigen. Mol Cells. 2002;13:288-295.
16. Park MS, Park JW, Jeon CH, et al. Expression of melanoma antigen-encoding genes (MAGE) by common primers for MAGE-A1 to -A6 in colorectal carcinomas among Koreans. J Korean Med Sci. 2002;17:497-501.
17. Patard JJ, Brasseur F, Gil-Diez S, et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer. 1995;64:60-64.
18. Ringhoffer M, Schmitt M, Karbach J, et al. Quantitative assessment of the expression of melanoma-associated antigens by non-competitive reverse transcription polymerase chain reaction. Int J Oncol. 2001;19:983-989.
19. Salgaller ML, Weber JS, Koenig S, et al. Generation of specific antimelanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 1994;39:105-116.
20. Tartaglia J, Bonnet MC, Berinstein N, et al. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine. 2001;19:2571-2575.
21. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
22. Xu X, Chu AY, Pasha TL, et al. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol. 2002;26:82-87.
23. Zakut R, Topalian SL, Kawakami Y, et al. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res. 1993;53:5-8.
24. Zuber M, Spagnoli GC, Kocher T, et al. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Eur Surg Res. 1997;29:403-410.
25. What you need to know about melanoma [National Cancer Institute/Cancer. gov website], March 31, 2003. Available at http://www.nci.nih. gov/cancerinfo/wyntk/melanoma#top. Accessed April 20, 2003